Reumatismo最新文献

筛选
英文 中文
To prophylax or not to prophylax? The role of trimethoprim/sulfamethoxazole as a prophylactic agent in systemic vasculitis: the case of antineutrophil cytoplasmic antibody- associated vasculitis and giant cell arteritis.
IF 1.2
Reumatismo Pub Date : 2025-02-13 DOI: 10.4081/reumatismo.2025.1791
Alessandro Tomelleri, Christian Dejaco, Milena Bond
{"title":"To prophylax or not to prophylax? The role of trimethoprim/sulfamethoxazole as a prophylactic agent in systemic vasculitis: the case of antineutrophil cytoplasmic antibody- associated vasculitis and giant cell arteritis.","authors":"Alessandro Tomelleri, Christian Dejaco, Milena Bond","doi":"10.4081/reumatismo.2025.1791","DOIUrl":"https://doi.org/10.4081/reumatismo.2025.1791","url":null,"abstract":"<p><p>Inflammatory rheumatic and musculoskeletal diseases, including systemic vasculitis, increase the risk of infection due to immunosuppressive treatments and disease-related immune dysfunction. In this viewpoint, we focused on patients with antineutrophil cytoplasmic antibody-associated vasculitis (AAV) and giant cell arteritis (GCA). We critically reviewed the literature on infectious risks and the role of trimethoprim/sulfamethoxazole (TMP/SMX) as a prophylactic agent in these conditions. In AAV, serious infections from opportunistic (e.g., Pneumocystis jirovecii) and non-opportunistic pathogens are especially common, peaking in the first year post-diagnosis. TMP/SMX is crucial for prevention, as its use significantly reduces the incidence of Pneumocystis jirovecii pneumonia (PJP) and other serious infections. In GCA, although the risk of PJP is low, the overall infection risk is high and correlates with glucocorticoid dosage. However, evidence supporting the routine use of TMP/SMX in GCA is limited, warranting further investigation through randomized clinical trials.</p>","PeriodicalId":21222,"journal":{"name":"Reumatismo","volume":" ","pages":""},"PeriodicalIF":1.2,"publicationDate":"2025-02-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143410398","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
The Italian Society for Rheumatology guidelines on reproductive health in patients with rheumatic diseases.
IF 1.2
Reumatismo Pub Date : 2025-02-12 DOI: 10.4081/reumatismo.2025.1752
Chiara Crotti, Nicola Ughi, Emanuela Beretta, Antonio Luca Brucato, Greta Carrara, Maria Sole Chimenti, Paola Conigliaro, Francesca Crisafulli, Giovanna Cuomo, Emma Di Poi, Khadija El Auofy, Micaela Fredi, Maria Chiara Gerardi, Maria Gerosa, Ariela Hoxa, Aurora Ianniello, Maddalena Larosa, Danila Morano, Marta Mosca, Mario Motta, Martina Orlandi, Melissa Padovan, Davide Rozza, Savino Sciascia, Silvia Tonolo, Simona Truglia, Maria Letizia Urban, Anna Zanetti, Sonia Zatti, Angela Tincani
{"title":"The Italian Society for Rheumatology guidelines on reproductive health in patients with rheumatic diseases.","authors":"Chiara Crotti, Nicola Ughi, Emanuela Beretta, Antonio Luca Brucato, Greta Carrara, Maria Sole Chimenti, Paola Conigliaro, Francesca Crisafulli, Giovanna Cuomo, Emma Di Poi, Khadija El Auofy, Micaela Fredi, Maria Chiara Gerardi, Maria Gerosa, Ariela Hoxa, Aurora Ianniello, Maddalena Larosa, Danila Morano, Marta Mosca, Mario Motta, Martina Orlandi, Melissa Padovan, Davide Rozza, Savino Sciascia, Silvia Tonolo, Simona Truglia, Maria Letizia Urban, Anna Zanetti, Sonia Zatti, Angela Tincani","doi":"10.4081/reumatismo.2025.1752","DOIUrl":"https://doi.org/10.4081/reumatismo.2025.1752","url":null,"abstract":"<p><strong>Objective: </strong>To date, there is no shared national guideline in Italy for the management of reproductive health in rheumatic diseases (RHRD). The Italian Society for Rheumatology has committed to developing clinical practice recommendations to provide guidance on both management and treatment regarding RHRD in Italy.</p><p><strong>Methods: </strong>Using the GRADE-ADOLOPMENT methodology, a systematic literature review was conducted to update the scientific evidence that emerged after the publication of the reference recommendations from the American College of Rheumatology. A multidisciplinary group of 18 clinicians with specialist experience in rheumatology, allergy and clinical immunology, internal medicine, nephrology, gynecology and obstetrics, and neonatology, a professional nurse, a clinical psychologist, and a representative from the National Association of Rheumatic Patients discussed the recommendations in collaboration with the evidence review working group. Subsequently, a group of stakeholders was consulted to examine and externally evaluate the developed recommendations.</p><p><strong>Results: </strong>Recommendations were formulated for each area of interest: contraception, assisted reproductive technology, preconception counseling, and use of drugs before, during, and after pregnancy and during breastfeeding, considering both paternal and maternal exposure.</p><p><strong>Conclusions: </strong>The new SIR recommendations provide the rheumatology community with a practical guide based on updated scientific evidence for the management of RHRD.</p>","PeriodicalId":21222,"journal":{"name":"Reumatismo","volume":" ","pages":""},"PeriodicalIF":1.2,"publicationDate":"2025-02-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143410396","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Antisynthetase syndrome with anti-glycyl tRNA synthetase antibodies in a patient with axial spondyloarthritis treated with tumor necrosis factor-α inhibitors.
IF 1.2
Reumatismo Pub Date : 2025-02-10 DOI: 10.4081/reumatismo.2025.1756
Maria Iacovantuono, Chiara Bonini, Ernesto Di Biase, Vinicio Magliacani, Gian Domenico Sebastiani
{"title":"Antisynthetase syndrome with anti-glycyl tRNA synthetase antibodies in a patient with axial spondyloarthritis treated with tumor necrosis factor-α inhibitors.","authors":"Maria Iacovantuono, Chiara Bonini, Ernesto Di Biase, Vinicio Magliacani, Gian Domenico Sebastiani","doi":"10.4081/reumatismo.2025.1756","DOIUrl":"https://doi.org/10.4081/reumatismo.2025.1756","url":null,"abstract":"<p><p>We present a case of interstitial lung disease arising in the course of antisynthetase syndrome (ASSD) in a patient with axial spondyloarthritis (ax-SpA) undergoing tumor necrosis factor-α (TNF-α) inhibitors therapy. Only two cases of ASSD in ax-SpA patients have been described in the literature, although with a different autoantibody profile. Only in one case, ASSD manifested with lung involvement, without the possible implication of TNF-α inhibitors in the pathogenesis, as it occurred concurrently with spondyloarthritis. Our case is the first to emphasize the coexistence of ASSD with anti-glycyl tRNA synthetase antibodies and ax-SpA, reminding us of the possible, although rare, adverse effects on the lungs with TNF-α inhibitors.</p>","PeriodicalId":21222,"journal":{"name":"Reumatismo","volume":" ","pages":""},"PeriodicalIF":1.2,"publicationDate":"2025-02-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143391661","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Janus kinase inhibitors in rheumatoid arthritis-associated interstitial lung disease: where do we stand and what may be the future?
IF 1.2
Reumatismo Pub Date : 2025-01-29 DOI: 10.4081/reumatismo.2025.1754
Beatrice Maranini, Roberta Foti, Moustapha Taha, Veronica Venturelli, Andrea Lo Monaco, Marcello Govoni
{"title":"Janus kinase inhibitors in rheumatoid arthritis-associated interstitial lung disease: where do we stand and what may be the future?","authors":"Beatrice Maranini, Roberta Foti, Moustapha Taha, Veronica Venturelli, Andrea Lo Monaco, Marcello Govoni","doi":"10.4081/reumatismo.2025.1754","DOIUrl":"https://doi.org/10.4081/reumatismo.2025.1754","url":null,"abstract":"<p><strong>Objective: </strong>Interstitial lung disease (ILD) is rare, but it is one of the most frequent extra-articular manifestations and a relevant cause of morbidity and mortality in rheumatoid arthritis (RA). Over the past few years, Janus kinase inhibitors (JAKis) have been reported to have promising efficacy in the treatment of active RA, but recent concerns have been raised about their safety profile, namely malignancy and cardiovascular disease, limiting their use to certain patient categories.</p><p><strong>Methods: </strong>The objective of this narrative review is to summarize the current evidence of the efficacy and safety of JAKis in RA-ILD management, investigating a possible emerging role for this drug class in such subset of patients.</p><p><strong>Results: </strong>Current studies focusing on JAKis in RA-ILD are scarce, but they globally report an overall stabilization of respiratory symptoms, functional data, and radiographic extension of ILD. In some cohorts, JAKis determined even an encouraging improvement in lung disease, and few reports presented good tolerability of JAKis in combination with antifibrotics. Concerning the safety profile, no significant increased risk of pulmonary infection has been reported.</p><p><strong>Conclusions: </strong>Thus far, evidence regarding the role of JAKis in the treatment of RA-ILD remains relatively limited, and additional prospective studies are needed to better understand the place of JAKis, if any, in preventing/stabilizing ILD in RA patients.</p>","PeriodicalId":21222,"journal":{"name":"Reumatismo","volume":" ","pages":""},"PeriodicalIF":1.2,"publicationDate":"2025-01-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143067656","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Real-world clinical experience with secukinumab in psoriatic arthritis: an observational study and a literature review.
IF 1.2
Reumatismo Pub Date : 2025-01-27 DOI: 10.4081/reumatismo.2025.1694
Eleonora Celletti, Giulio Gualdi, Emanuela Sabatini, Francesco Cipollone, Fabio Lobefaro, Paolo Amerio
{"title":"Real-world clinical experience with secukinumab in psoriatic arthritis: an observational study and a literature review.","authors":"Eleonora Celletti, Giulio Gualdi, Emanuela Sabatini, Francesco Cipollone, Fabio Lobefaro, Paolo Amerio","doi":"10.4081/reumatismo.2025.1694","DOIUrl":"https://doi.org/10.4081/reumatismo.2025.1694","url":null,"abstract":"<p><strong>Objective: </strong>Psoriatic arthritis (PsA) can be treated with biological drugs targeting IL-17A, such as secukinumab, with good responses and long-term positive outcomes in clinical studies.</p><p><strong>Methods: </strong>An observational study was conducted on adult subjects with PsA and comorbidities, treated with secukinumab after prior therapy with conventional disease-modifying anti-rheumatic drugs or biological agents that were discontinued due to lack of efficacy or adverse drug reactions. Patients were followed up with clinical visits at 3, 6, 9, and 12 months and evaluated for disease activity, pain, and quality of life, with respect to values recorded at baseline. Moreover, a narrative review of the literature was performed on secukinumab's use for PsA in real life.</p><p><strong>Results: </strong>Fifteen patients completed 6 months of follow-up, eleven patients completed 9 months, and six patients were followed for 12 months. The major comorbidities recorded were fibromyalgia (33% of patients), recurrent bilateral anterior uveitis, and autoimmune thyroiditis with hypothyroidism (both 13% of the patients). A significant improvement in Disease Activity Score-28 was recorded at 6 and 9 months, while a significant difference vs. baseline was seen at 3, 6, and 9 months for the Psoriasis Area Severity Index. The Bath Ankylosing Spondylitis Disease Activity Index showed significant differences vs. baseline at 9 and 12 months. There was an improving trend at 9 and 12 months for pain scores and a significant improvement at 6 and 9 months for the physical component and at 12 months for the social component (Short Form 36 Health Survey quality of life scores). For the review of the literature, 35 articles were identified but only 17 papers were eventually considered.</p><p><strong>Conclusions: </strong>Secukinumab has demonstrated effectiveness for PsA treatment in several real-world studies. Both patient-oriented and clinician-oriented outcomes showed a significant improvement with this treatment. The present real-world evaluation adds further evidence of the use of secukinumab for PsA treatment, showing the rapid, safe, clinically significant, and sustained responses of PsA patients affected by co-morbidities.</p>","PeriodicalId":21222,"journal":{"name":"Reumatismo","volume":" ","pages":""},"PeriodicalIF":1.2,"publicationDate":"2025-01-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143047640","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Adherence to vaccination against SARS-CoV-2 and vaccine safety in patients with immunoglobulin G4-related disease.
IF 1.2
Reumatismo Pub Date : 2025-01-22 DOI: 10.4081/reumatismo.2025.1744
Linda Mastromanno, Federico Giardina, Angelica Gattamelata, Serena Colafrancesco, Simona Truglia, Francesca Romana Spinelli, Edoardo Simoncelli, Bruno Lucchino, Fabrizio Conti, Roberta Priori
{"title":"Adherence to vaccination against SARS-CoV-2 and vaccine safety in patients with immunoglobulin G4-related disease.","authors":"Linda Mastromanno, Federico Giardina, Angelica Gattamelata, Serena Colafrancesco, Simona Truglia, Francesca Romana Spinelli, Edoardo Simoncelli, Bruno Lucchino, Fabrizio Conti, Roberta Priori","doi":"10.4081/reumatismo.2025.1744","DOIUrl":"https://doi.org/10.4081/reumatismo.2025.1744","url":null,"abstract":"<p><strong>Objective: </strong>To assess the adherence to the vaccination campaign against SARS-CoV-2 in patients with immunoglobulin-G4-related disease (IgG4-RD) and to evaluate the development of local and systemic adverse events (AEs) following vaccination. Additionally, to investigate the rate and outcome of SARS-CoV-2 infection in IgG4-RD patients.</p><p><strong>Methods: </strong>Patients with IgG4-RD in follow-up before the onset of the SARS-CoV-2 pandemic were contacted by telephone and asked to answer an ad hoc questionnaire regarding their vaccination status against SARS-CoV-2 and related AEs following vaccination. The occurrence and the outcome of SARS-CoV-2 infection were also recorded. The same questionnaire was proposed to healthy controls (HC).</p><p><strong>Results: </strong>20 patients and 40 HC were enrolled. In the patient's cohort, 90% were vaccinated with at least one dose; among them, 9 reported AEs: 44.4% systemic and 22.2% local. Within the HC group, 100% were vaccinated with at least one dose. 13 out of 40 HC had systemic AEs (50%), and 27 (67.5%) reported local AEs. Neither in IgG4-RD nor in HC, serious adverse reactions were observed. Among the patient's cohort, 60% contracted SARS-CoV-2 infection, and 41.67% were on immunosuppressants at the time of the infection. One patient presented with severe COVID-19. No disease flares following vaccination or infection were reported.</p><p><strong>Conclusions: </strong>Results from our study indicate a good adherence to the vaccination campaign against SARS-CoV-2 in patients with IgG4-RD and support a relatively good safety profile of this vaccine. Compared to controls, patients with IgG4-RD reported slightly more systemic AEs and fewer local AEs. A similar rate of COVID-19 development was observed between IgG4-RD patients and HC.</p>","PeriodicalId":21222,"journal":{"name":"Reumatismo","volume":" ","pages":""},"PeriodicalIF":1.2,"publicationDate":"2025-01-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143029558","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Small molecules in idiopathic inflammatory myopathies: a systematic review and a multicenter case series about Janus kinase inhibitors and apremilast. 特发性炎性肌病中的小分子:关于Janus激酶抑制剂和阿普米司特的系统回顾和多中心病例系列。
IF 1.2
Reumatismo Pub Date : 2025-01-13 DOI: 10.4081/reumatismo.2025.1718
Chiara Rizzo, Silvia Grazzini, Edoardo Conticini, Hector Chinoy, Roberto D'Alessandro, Federica Camarda, Luca Cantarini, Bruno Frediani, Giuliana Guggino, Lidia La Barbera
{"title":"Small molecules in idiopathic inflammatory myopathies: a systematic review and a multicenter case series about Janus kinase inhibitors and apremilast.","authors":"Chiara Rizzo, Silvia Grazzini, Edoardo Conticini, Hector Chinoy, Roberto D'Alessandro, Federica Camarda, Luca Cantarini, Bruno Frediani, Giuliana Guggino, Lidia La Barbera","doi":"10.4081/reumatismo.2025.1718","DOIUrl":"https://doi.org/10.4081/reumatismo.2025.1718","url":null,"abstract":"<p><strong>Objective: </strong>Idiopathic inflammatory myopathies (IIM) are rare autoimmune diseases that primarily affect striated muscles; skin, joints, and lungs may be involved with different degrees of severity. Traditional treatment relies on high-dose glucocorticoids and conventional synthetic disease-modifying antirheumatic drugs.</p><p><strong>Methods: </strong>A growing amount of evidence is demonstrating the potential role of novel treatments in the management of IIM. We report our experience with Janus kinase inhibitors (JAKi) in these conditions and review the current evidence for the use of small molecules in real-life clinical practice.</p><p><strong>Results: </strong>A total of 41 papers were retrieved from PubMed, 37 papers concerning IIM and JAKi, and 4 papers concerning IIM and apremilast.</p><p><strong>Conclusions: </strong>An overall good efficacy was evidenced in IIM-associated skin lesions, including rash, ulcers, and calcinosis. If present, muscle and joint involvement demonstrated a good response to therapy, while it was not possible to draw any conclusion about dysphagia. No life-threatening adverse events were reported.</p>","PeriodicalId":21222,"journal":{"name":"Reumatismo","volume":" ","pages":""},"PeriodicalIF":1.2,"publicationDate":"2025-01-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142984652","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Coexisting rheumatoid arthritis and sickle cell disease: case series and literature review. 并发类风湿关节炎和镰状细胞病:病例系列和文献回顾。
IF 1.2
Reumatismo Pub Date : 2025-01-07 DOI: 10.4081/reumatismo.2025.1682
Abdallah Alqethami, Sabri Alsaeedi, Samera Felemban, Abdulelah Qadi
{"title":"Coexisting rheumatoid arthritis and sickle cell disease: case series and literature review.","authors":"Abdallah Alqethami, Sabri Alsaeedi, Samera Felemban, Abdulelah Qadi","doi":"10.4081/reumatismo.2025.1682","DOIUrl":"https://doi.org/10.4081/reumatismo.2025.1682","url":null,"abstract":"<p><p>Rheumatoid arthritis (RA) is rarely reported among patients with sickle cell disease (SCD). RA treatment in these patients is believed to be more challenging due to fear of increasing the risk of infection and complications of SCD. We are reporting 7 patients with concurrent SCD and RA. The average age at the time of the diagnosis of RA was 33.3±12.6 years (ranging from 16 to 53 years), and most were women (5/7). Most of the patients were positive for rheumatoid factor (6/7) or anticyclic citrullinated peptide (6/7). Four patients were treated with hydroxyurea. The most used antirheumatic drugs were methotrexate (7/7), biologic agents (5/7), and prednisone (4/7). Two patients were in remission, four had low and one had high disease activity. Four patients (4/7) had avascular necrosis, two in the shoulders and two in the hip joints. Four patients had emergency visits or hospitalizations within one year of the diagnosis of RA, but none had blood transfusions, infections, or death. The start of antirheumatic medication was not associated with an increased risk of infection, blood transfusions, emergency visits, or hospitalizations, nor with a worsening of laboratory measures. The findings suggest that the treatment of RA in patients with SCD should follow the same strategy as in patients without SCD. However, treatment should be individualized according to the individual patient's risk of infection and SCD complications.</p>","PeriodicalId":21222,"journal":{"name":"Reumatismo","volume":" ","pages":""},"PeriodicalIF":1.2,"publicationDate":"2025-01-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142954111","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Retrospective evaluation of the efficacy of ultrasound-guided intra-articular hyaluronic-acid- based injections (Hyalubrix®) in patients with glenohumeral osteoarthritis. 超声引导下关节内透明质酸注射(Hyalubrix®)治疗盂肱骨关节炎疗效的回顾性评价。
IF 1.2
Reumatismo Pub Date : 2024-12-16 DOI: 10.4081/reumatismo.2024.1699
L Monti, E Franchi, F Verde, S Sgherzi, F M Anghilieri
{"title":"Retrospective evaluation of the efficacy of ultrasound-guided intra-articular hyaluronic-acid- based injections (Hyalubrix<sup>®</sup>) in patients with glenohumeral osteoarthritis.","authors":"L Monti, E Franchi, F Verde, S Sgherzi, F M Anghilieri","doi":"10.4081/reumatismo.2024.1699","DOIUrl":"https://doi.org/10.4081/reumatismo.2024.1699","url":null,"abstract":"<p><strong>Objective: </strong>Intra-articular injections of hyaluronic acid (HA) have been reported to alleviate pain, reduce disability, and improve joint function in glenohumeral osteoarthritis (GH-OA). This retrospective study aimed to evaluate the effectiveness of a HA-based formulation (Hyalubrix®) in reducing the pain of patients with GH-OA and improving both patient's shoulder functions and quality of life (QoL).</p><p><strong>Methods: </strong>Data collected during the standard clinical practice of the center was retrospectively analyzed. The Simple Shoulder Test (SST) questionnaire reported data on the patient's ability to perform daily activities; the Euro-Quality of Life Health Assessment (EQ-5D) collected evidence on QoL; and changes in pain were evaluated through the Visual Analog Scale (VAS). SST and EQ-5D scores were analyzed comparing baseline values with those at the last follow-up, while VAS was investigated for all the available visits. Continuous values were summarized as mean ± standard deviation, median, and 25-75th percentiles. Shapiro-Wilk test assessed normality, with significance set at p<0.05, and no adjustments for multiple comparisons were made.</p><p><strong>Results: </strong>All scores showed a significant improvement: VAS decreased from 55.4±13.8 to 16.2±16.3 (p<0.001), the SST increased from 38.0 to 65.5 (p<0.001), as well as the EQ-5D (from 41.7 to 76.7; p<0.001).</p><p><strong>Conclusions: </strong>GH-OA treatment with Hyalubrix® proved to be highly beneficial, leading to complete pain reduction in more than 50% of patients and a significant reduction in 27.5% of cases. This resulted in improved joint function and QoL.</p>","PeriodicalId":21222,"journal":{"name":"Reumatismo","volume":" ","pages":""},"PeriodicalIF":1.2,"publicationDate":"2024-12-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142838440","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
The holistic management of peripheral spondyloarthritis: focus on articular involvement in patients with inflammatory bowel disease. 外周脊柱关节炎的综合治疗:关注炎症性肠病患者的关节受累情况。
IF 1.2
Reumatismo Pub Date : 2024-11-11 DOI: 10.4081/reumatismo.2024.1688
E Lubrano, A Armuzzi, S Scriffignano, C Felice, F M Perrotta, V Venerito, S Del Vescovo, R Ramonda, G Cassone, F Atzeni, R Caporali, F Conti, E Gremese, F Iannone, M Sebastiani, E G Favalli
{"title":"The holistic management of peripheral spondyloarthritis: focus on articular involvement in patients with inflammatory bowel disease.","authors":"E Lubrano, A Armuzzi, S Scriffignano, C Felice, F M Perrotta, V Venerito, S Del Vescovo, R Ramonda, G Cassone, F Atzeni, R Caporali, F Conti, E Gremese, F Iannone, M Sebastiani, E G Favalli","doi":"10.4081/reumatismo.2024.1688","DOIUrl":"https://doi.org/10.4081/reumatismo.2024.1688","url":null,"abstract":"<p><strong>Objective: </strong>To provide a comprehensive overview of peripheral spondyloarthritis (pSpA), focusing specifically on its occurrence and management in patients with inflammatory bowel disease (IBD).</p><p><strong>Methods: </strong>An exhaustive literature search was conducted in PubMed, Embase, Cochrane Database of Systematic Reviews, and Google Scholar to identify relevant studies on pSpA in IBD patients. Titles, abstracts, and full-text articles were screened for relevance. Data on study design, patient characteristics, diagnostic criteria, main findings, and conclusions were extracted from selected articles. Study quality was assessed using appropriate checklists. Information was synthesized narratively to summarize current understanding.</p><p><strong>Results: </strong>pSpA is the most common extraintestinal manifestation in IBD, with a median prevalence of 16%. It worsens quality of life and requires collaboration between gastroenterologists and rheumatologists for optimal diagnosis and treatment. Several \"red flags\" guide appropriate specialist referral of IBD patients with suspected pSpA. Once the diagnosis is confirmed, the choice of therapy depends on IBD phenotype and patterns of articular/axial involvement. Anti-tumor necrosis factor (TNF) drugs are first-line biologics, with interleukin (IL)-12/23 and IL-23 inhibitors as alternatives for anti-TNF failure. Small molecules like apremilast and Janus kinase inhibitors also have utility. Recommended treatment algorithms exist, but more randomized controlled trials are needed.</p><p><strong>Conclusions: </strong>Early identification of pSpA is crucial in IBD patients to enable timely intervention, prevent structural damage, and minimize disability. A multidisciplinary, holistic approach addressing musculoskeletal and extra-musculoskeletal manifestations is key to optimal patient outcomes.</p>","PeriodicalId":21222,"journal":{"name":"Reumatismo","volume":" ","pages":""},"PeriodicalIF":1.2,"publicationDate":"2024-11-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142625536","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
相关产品
×
本文献相关产品
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信